Fig. 3

ROS scavenging activity of 7CZ nanomedicines in vitro. a Schematic illustration of the protective effect of 7CZ nanomedicines by redox-mediated ROS elimination. b Cytotoxicity of 7CZ nanomedicines in podocytes within 24 h. c Representative fluorescent microscope images of podocytes incubated with FITC-7CZ nanomedicines for 3 and 6 h are displayed. DAPI, blue; FITC-7CZ nanomedicines, green. Scale bar: 200 μm. d Intracellular ROS scavenging capability of 7CZ nanomedicines after different treatments for 24 h by DCFH-DA. Scale bar: 200 μm. e Qualitative analysis of ROS levels in podocytes after different treatments for 24 h. f Flow-cytometry-based apoptosis assay of cell apoptosis distribution in podocytes after different treatments. Data are presented as mean ± SD, one-way ANOVA, ns, non-significance, *P < 0.05, **P < 0.01; ***P < 0.001, ****P < 0.0001, vs. ADR group